151 related articles for article (PubMed ID: 2972233)
1. Clinical pharmacology of doxacurium chloride. A new long-acting nondepolarizing muscle relaxant.
Basta SJ; Savarese JJ; Ali HH; Embree PB; Schwartz AF; Rudd GD; Wastila WB
Anesthesiology; 1988 Oct; 69(4):478-86. PubMed ID: 2972233
[TBL] [Abstract][Full Text] [Related]
2. The neuromuscular blocking and cardiovascular effects of doxacurium chloride in patients receiving nitrous oxide narcotic anesthesia.
Murray DJ; Mehta MP; Choi WW; Forbes RB; Sokoll MD; Gergis SD; Rudd GD; Abou-Donia MM
Anesthesiology; 1988 Oct; 69(4):472-7. PubMed ID: 3177909
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology of doxacurium chloride (BW A938U) in children.
Sarner JB; Brandom BW; Cook DR; Dong ML; Horn MC; Woelfel SK; Davis PJ; Rudd GD; Foster VJ; McNulty BF
Anesth Analg; 1988 Apr; 67(4):303-6. PubMed ID: 2965532
[TBL] [Abstract][Full Text] [Related]
4. Reversal of doxacurium and pancuronium neuromuscular blockade with neostigmine in children.
Bevan JC; Purday JP; Reimer EJ; Bevan DR
Can J Anaesth; 1994 Nov; 41(11):1074-80. PubMed ID: 7828255
[TBL] [Abstract][Full Text] [Related]
5. The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U). A short-acting nondepolarizing ester neuromuscular blocking drug.
Savarese JJ; Ali HH; Basta SJ; Embree PB; Scott RP; Sunder N; Weakly JN; Wastila WB; el-Sayad HA
Anesthesiology; 1988 May; 68(5):723-32. PubMed ID: 2967039
[TBL] [Abstract][Full Text] [Related]
6. Neuromuscular block with doxacurium (BW A938U) in patients with normal or absent renal function.
Cashman JN; Luke JJ; Jones RM
Br J Anaesth; 1990 Feb; 64(2):186-92. PubMed ID: 2138489
[TBL] [Abstract][Full Text] [Related]
7. Neuromuscular and cardiovascular effects of doxacurium in children anaesthetized with halothane.
Goudsouzian NG; Alifimoff JK; Liu LM; Foster V; McNulty B; Savarese JJ
Br J Anaesth; 1989 Mar; 62(3):263-8. PubMed ID: 2522789
[TBL] [Abstract][Full Text] [Related]
8. The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia.
Lien CA; Belmont MR; Abalos A; Eppich L; Quessy S; Abou-Donia MM; Savarese JJ
Anesthesiology; 1995 May; 82(5):1131-8. PubMed ID: 7537945
[TBL] [Abstract][Full Text] [Related]
9. Comparison of neuromuscular, cardiovascular, and histamine-releasing properties of doxacurium and pipecuronium.
Denman WT; Goudsouzian NG; Gelb C
J Clin Anesth; 1996 Mar; 8(2):113-8. PubMed ID: 8695092
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, randomized, multicenter study of doxacurium vs. pancuronium in intensive care unit patients who require neuromuscular-blocking agents.
Murray MJ; Coursin DB; Scuderi PE; Kamath G; Prough DS; Howard DM; Abou-Donia MA
Crit Care Med; 1995 Mar; 23(3):450-8. PubMed ID: 7874894
[TBL] [Abstract][Full Text] [Related]
11. Dose-response relations of doxacurium and its reversal with neostigmine in young adults and healthy elderly patients.
Koscielniak-Nielsen ZJ; Law-Min JC; Donati F; Bevan DR; Clement P; Wise R
Anesth Analg; 1992 Jun; 74(6):845-50. PubMed ID: 1534472
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular effects of doxacurium, pancuronium and vecuronium in anaesthetized patients presenting for coronary artery bypass surgery.
Emmott RS; Bracey BJ; Goldhill DR; Yate PM; Flynn PJ
Br J Anaesth; 1990 Oct; 65(4):480-6. PubMed ID: 1979009
[TBL] [Abstract][Full Text] [Related]
13. Train-of-four recovery after pharmacologic antagonism of pancuronium-, pipecuronium-, and doxacurium-induced neuromuscular block in anaesthetized humans.
Stinson LW; Lanier WL; Lennon RL
Acta Anaesthesiol Scand; 1995 Apr; 39(3):406-10. PubMed ID: 7793225
[TBL] [Abstract][Full Text] [Related]
14. Hemodynamic and pharmacodynamic comparison of doxacurium and pipecuronium with pancuronium during induction of cardiac anesthesia: does the benefit justify the cost?
Rathmell JP; Brooker RF; Prielipp RC; Butterworth JF; Gravlee GP
Anesth Analg; 1993 Mar; 76(3):513-9. PubMed ID: 8383933
[TBL] [Abstract][Full Text] [Related]
15. Doxacurium. A review of its pharmacology and clinical potential in anaesthesia.
Faulds D; Clissold SP
Drugs; 1991 Oct; 42(4):673-89. PubMed ID: 1723368
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of doxacurium chloride.
Maddineni VR; Cooper R; Stanley JC; Mirakhur RK; Clarke RS
Anaesthesia; 1992 Jul; 47(7):554-7. PubMed ID: 1385680
[TBL] [Abstract][Full Text] [Related]
17. Long-acting nondepolarizing neuromuscular blocking agents.
Embree PB
AANA J; 1993 Aug; 61(4):382-7. PubMed ID: 8397465
[TBL] [Abstract][Full Text] [Related]
18. Doxacurium chloride for neuromuscular blockade before tracheal intubation and surgery during nitrous oxide-oxygen-narcotic-enflurane anesthesia.
Lennon RL; Hosking MP; Houck PC; Rose SH; Wedel DJ; Gibson BE; Ascher JA; Rudd GD
Anesth Analg; 1989 Mar; 68(3):255-60. PubMed ID: 2919763
[TBL] [Abstract][Full Text] [Related]
19. Neuromuscular effects of doxacurium chloride in isoflurane-anesthetized dogs.
Martinez EA; Wooldridge AA; Hartsfield SM; Mealey KL
Vet Surg; 1998; 27(3):279-83. PubMed ID: 9605239
[TBL] [Abstract][Full Text] [Related]
20. Dose-response and Cardiopulmonary Side Effects of the Novel Neuromuscular-blocking Drug CW002 in Man.
Heerdt PM; Sunaga H; Owen JS; Murrell MT; Malhotra JK; Godfrey D; Steinkamp M; Savard P; Savarese JJ; Lien CA
Anesthesiology; 2016 Dec; 125(6):1136-1143. PubMed ID: 27749289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
